肺疾患治療薬の世界市場

肺疾患治療薬の世界市場は2030年までに1,060億米ドルに到達

2024年に806億米ドルと推定される肺疾患治療薬の世界市場は、2024～2030年の分析期間においてCAGR 4.7%で成長し、2030年には1,060億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである喘息疾患は、CAGR 4.4%を記録し、分析期間終了時には650億米ドルに達すると予測されます。肺がん疾患セグメントの成長率は、分析期間中CAGR 5.4%と推定されます。

米国市場は220億米ドルと推定、中国はCAGR 8.4%で成長予測

米国の肺疾患治療薬市場は2024年に220億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに220億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.0％と3.6％と予測されています。欧州では、ドイツがCAGR 2.7%で成長すると予測されています。

世界の肺疾患治療薬市場- 主要動向と促進要因のまとめ

なぜ肺疾患治療のパラダイムシフトが起きているのか？

肺疾患治療薬は、呼吸器疾患による世界の負担の増大と、より効果的で的を絞った持続可能な治療アプローチへのニーズの高まりに後押しされ、焦点の大幅なシフトと技術革新を経験しています。喘息、慢性閉塞性肺疾患（COPD）、特発性肺線維症（IPF）、肺高血圧症、間質性肺疾患などの慢性および急性の肺疾患は、大気汚染の増加、喫煙、職業性曝露、人口の高齢化などの要因により、より蔓延しつつあります。歴史的には、肺疾患は主に気管支拡張薬、コルチコステロイド、抗生物質によって管理されてきました。しかし、これらの治療は多くの場合、根本的な原因よりもむしろ症状に対処するものでした。最近の分子生物学、免疫学、薬理ゲノミクスの動向は、疾患のメカニズムや細胞経路を特異的に標的とする治療法の開発につながりました。モノクローナル抗体などの生物学的製剤や低分子阻害剤は、より正確に炎症を制御し、線維化を食い止め、肺機能を改善するように設計されています。吸入療法もまた、肺深部組織へのドラッグデリバリーをより確実にし、全身的副作用を最小限に抑えながら治療効果を向上させるよう、再設計されつつあります。治療法は、一般的な対症療法から、患者固有の診断や合併症を考慮した個別化ケアプランへと進化しています。特にCOVID-19の大流行後、呼吸器系の健康が世界の優先事項となっているため、先進的な肺疾患治療に対する需要はヘルスケアシステム全体で高まっています。このパラダイムシフトは、長期的な呼吸器疾患の予後を改善し、慢性肺疾患による経済的・社会的影響を軽減するという広範なコミットメントを反映しています。

革新的な治療アプローチは呼吸器疾患の管理をどのように再構築しているのか？

革新的な治療アプローチは、新しい薬剤クラス別、新しいデリバリーシステム、そして単に症状を管理するのではなく、疾患の進行を変化させることを目的とした再生医療戦略を導入することによって、肺疾患の管理を再構築しています。喘息やCOPDの場合、抗IgE抗体、抗IL-5抗体、抗IL-4受容体抗体などの標的生物学的製剤が、治療抵抗性の重症患者の転帰を変えつつあります。これらの生物学的製剤は特定の炎症経路を遮断し、従来の吸入薬だけでは達成できなかった方法で増悪を抑え、肺機能を改善します。肺線維症や間質性肺疾患では、ピルフェニドンやニンテダニブのような抗線維化剤が肺活量の低下を遅らせ、かつては治療不可能と考えられていた病態に希望をもたらしています。特に嚢胞性線維症のような希少な遺伝性肺疾患に対しては、遺伝子治療とRNAを用いた治療の統合が検討されており、根本的な遺伝的欠陥を長期的に改善できる可能性があります。幹細胞治療もまた、損傷した肺組織を再生し、呼吸機能を回復させる可能性について研究されています。さらに、スマート吸入器やデジタル治療薬の開発により、患者のアドヒアランスが向上し、接続されたデバイスや健康プラットフォームを通じて疾患コントロールのリアルタイムモニタリングが可能になりつつあります。これらのツールは使用データと環境インプットを収集し、臨床医が治療レジメンを最適化するのに役立っています。これらの最先端治療は、バイオマーカー検査や精密医療アプローチを通じて個々の患者プロファイルに合わせて調整され、従来の治療パラダイムをはるかに超えた、より個別化された効果的な肺疾患管理への道を開いています。

患者中心の肺疾患治療とモニタリングの新たな動向とは？

患者中心の治療とモニタリングは、個別化、利便性、長期的な疾患管理に重点を置くようになり、肺疾患治療薬の中心になりつつあります。慢性呼吸器疾患は生涯にわたる管理が必要とされることが多いため、ヘルスケア業界では臨床効果を確保しながら患者の体験を向上させる戦略の採用が進んでいます。注目すべき動向のひとつは、ポータブル酸素濃縮器、ネブライザー、遠隔医療プラットフォームなどに支えられた在宅ケアモデルの拡大であり、これにより患者は頻繁に病院を訪れることなく継続的なケアを受けることができます。ウェアラブルデバイスやモバイルアプリケーションを含む遠隔患者モニタリングツールは、酸素飽和度、ピーク流量、服薬アドヒアランスなどの重要な指標を追跡し、患者や介護者に実用的な洞察を与えます。薬理学的な進歩は、包括的なケアを提供するために、生活習慣管理プログラム、禁煙サポート、肺リハビリテーション、栄養カウンセリングと組み合わされています。治療計画は、患者の嗜好、遺伝的体質、環境曝露歴などに基づいて構築されることが多くなり、コンプライアンスと治療成績の向上が図られています。肺専門医、プライマリ・ケア提供者、薬剤師、呼吸療法士による多職種連携は、ケア連携を改善し、病院での再入院を減少させています。人工知能を搭載した臨床判断支援システムは、リアルタイムの患者データに基づいて最善の治療法を特定するのに役立っています。さらに、教育キャンペーンや患者擁護団体が、認知度の向上、早期診断の改善、新しい治療法へのアクセスの擁護において重要な役割を果たしています。このような新たな動向は、症状管理だけでなく、慢性肺疾患患者のQOL（生活の質）と長期的な呼吸器系の健康を向上させることを目標とする、価値観に基づいた医療を目指すヘルスケア全体の動きを反映しています。

世界の肺疾患治療薬市場の成長を促進する主な要因は？

世界の肺疾患治療薬市場の成長は、人口統計学的、環境的、技術的、政策的要因の組み合わせによってもたらされています。主要な促進要因は、世界の慢性呼吸器疾患の有病率の増加であり、特に都市化・工業化地域における大気汚染、タバコの使用、座りがちなライフスタイル、人口の高齢化が拍車をかけています。このような疾病負担の増大により、ヘルスケアシステムと政府は、先進的な診断ツール、スクリーニング・プログラムの拡大、治療へのアクセスの拡大など、呼吸器ケアに多くのリソースを割り当てるよう促しています。生物学的製剤や低分子治療薬を含む新薬の開発・承認により、治療の選択肢が拡大し、これまで十分な治療を受けてこなかった患者集団のニーズも満たされつつあります。大規模臨床試験と官民パートナーシップに支えられた製薬研究の勢いは、迅速な技術革新と迅速な承認取得を促進しています。さらに、デジタルヘルスソリューションや遠隔モニタリングツールの普及が進み、より効率的で費用対効果の高い肺疾患の管理が可能となっています。先進治療に対する医療保険の適用範囲も多くの国で改善されつつあり、導入とアクセスの拡大を後押ししています。COVID-19の世界的大流行を受けて呼吸器の健康に対する意識が高まり、肺の研究とインフラへの投資がさらに加速しています。さらに、個別化医療や精密医療が重視されるようになったことで、企業は副作用を最小限に抑えながら患者の転帰を改善する標的療法の開発を進めています。これらの促進要因が相まって、肺疾患治療薬市場は世界ヘルスケアにおける重要な柱として、また科学的にも商業的にも引き続き注目される分野として位置づけられ、ダイナミックで力強い成長環境が構築されつつあります。

セグメント

疾患（喘息疾患、肺がん疾患、慢性閉塞性肺疾患）;薬剤クラス別（副腎皮質ステロイド薬、気管支拡張薬、抗菌薬、アルキル化薬、粘液溶解薬）;治療（化学療法、免疫療法、標的療法、放射線療法）

調査対象企業の例

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb
• Chiesi Farmaceutici S.p.A.
• Cipla Ltd
• Gilead Sciences
• GlaxoSmithKline plc（GSK）
• Hoffmann-La Roche Ltd（Roche）
• Ionis Pharmaceuticals Inc.
• Johnson & Johnson（Janssen）
• Merck & Co. Inc.
• Mylan N.V.（part of Viatris）
• Nektar Therapeutics Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Incorporated

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Lung Disease Therapeutics Market to Reach US$106.0 Billion by 2030

The global market for Lung Disease Therapeutics estimated at US$80.6 Billion in the year 2024, is expected to reach US$106.0 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Asthma Disease, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$65.0 Billion by the end of the analysis period. Growth in the Lung Cancer Disease segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$22.0 Billion While China is Forecast to Grow at 8.4% CAGR

The Lung Disease Therapeutics market in the U.S. is estimated at US$22.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$22.0 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Lung Disease Therapeutics Market - Key Trends & Drivers Summarized

Why Is the Therapeutic Landscape for Lung Diseases Undergoing a Paradigm Shift?

Lung disease therapeutics are experiencing a significant shift in focus and innovation, driven by the growing global burden of respiratory illnesses and the increasing need for more effective, targeted, and sustainable treatment approaches. Chronic and acute lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and interstitial lung disease are becoming more prevalent due to factors such as rising air pollution, smoking, occupational exposures, and aging populations. Historically, lung conditions were managed primarily through bronchodilators, corticosteroids, and antibiotics. However, these treatments often addressed symptoms rather than underlying causes. In recent years, advances in molecular biology, immunology, and pharmacogenomics have led to the development of therapies that specifically target disease mechanisms and cellular pathways. Biologics, such as monoclonal antibodies, and small molecule inhibitors are being designed to control inflammation, halt fibrosis, and improve lung function with greater precision. Inhalation therapies are also being re-engineered to ensure better drug delivery to deep lung tissues, improving treatment efficacy while minimizing systemic side effects. The therapeutic landscape is evolving from generalized symptomatic relief to personalized care plans that integrate patient-specific diagnostics and comorbidity considerations. With respiratory health becoming a global priority, particularly following the COVID-19 pandemic, the demand for advanced lung disease treatments is intensifying across healthcare systems. This paradigm shift reflects a broader commitment to improving long-term respiratory outcomes and reducing the economic and societal impact of chronic lung conditions.

How Are Innovative Therapeutic Approaches Reshaping the Management of Respiratory Disorders?

Innovative therapeutic approaches are reshaping the management of lung diseases by introducing new classes of drugs, novel delivery systems, and regenerative medicine strategies aimed at altering disease progression rather than merely managing symptoms. In the case of asthma and COPD, targeted biologic therapies such as anti-IgE, anti-IL-5, and anti-IL-4 receptor antibodies are transforming outcomes for patients with severe, treatment-resistant forms of these conditions. These biologics block specific inflammatory pathways, reducing exacerbations and improving lung function in ways that traditional inhaled medications cannot achieve alone. In pulmonary fibrosis and interstitial lung diseases, antifibrotic agents like pirfenidone and nintedanib are slowing the decline in lung capacity, providing hope for conditions that were once considered untreatable. The integration of gene therapy and RNA-based treatments is under exploration, particularly for rare genetic lung diseases like cystic fibrosis, offering the potential for long-term correction of the underlying genetic defects. Stem cell therapies are also being investigated for their potential to regenerate damaged lung tissue and restore respiratory function. Additionally, the development of smart inhalers and digital therapeutics is improving patient adherence and enabling real-time monitoring of disease control through connected devices and health platforms. These tools collect usage data and environmental inputs, helping clinicians optimize treatment regimens. These cutting-edge therapies are being tailored to individual patient profiles through biomarker testing and precision medicine approaches, paving the way for more personalized and effective lung disease management that extends far beyond conventional treatment paradigms.

What Are the Emerging Trends in Patient-Centered Lung Disease Treatment and Monitoring?

Patient-centered treatment and monitoring are becoming central to lung disease therapeutics, with a growing emphasis on personalization, convenience, and long-term disease control. As chronic respiratory illnesses often require lifelong management, the healthcare industry is increasingly adopting strategies that enhance the patient experience while ensuring clinical effectiveness. One notable trend is the expansion of home-based care models, supported by portable oxygen concentrators, nebulizers, and telemedicine platforms that allow patients to receive ongoing care without frequent hospital visits. Remote patient monitoring tools, including wearable devices and mobile applications, track key indicators such as oxygen saturation, peak flow rates, and medication adherence, empowering patients and caregivers with actionable insights. Pharmacological advancements are being paired with lifestyle management programs, smoking cessation support, pulmonary rehabilitation, and nutrition counseling to deliver comprehensive care. Treatment plans are increasingly built around patient preferences, genetic makeup, and environmental exposure history to ensure better compliance and outcomes. Multidisciplinary collaboration among pulmonologists, primary care providers, pharmacists, and respiratory therapists is improving care coordination and reducing hospital readmissions. Clinical decision support systems powered by artificial intelligence are helping providers identify the best therapeutic options based on real-time patient data. Furthermore, education campaigns and patient advocacy groups are playing a key role in raising awareness, improving early diagnosis, and advocating for access to newer therapies. These emerging trends reflect a broader healthcare movement toward value-based care, where the goal is not only to manage symptoms but also to enhance quality of life and long-term respiratory well-being for those living with chronic lung disease.

What Are the Main Drivers Fueling the Growth of the Global Lung Disease Therapeutics Market?

The growth in the global lung disease therapeutics market is being driven by a combination of demographic, environmental, technological, and policy-related factors. A key driver is the increasing prevalence of chronic respiratory diseases worldwide, spurred by rising levels of air pollution, tobacco use, sedentary lifestyles, and aging populations, especially in urbanized and industrializing regions. This growing disease burden is prompting healthcare systems and governments to allocate more resources toward respiratory care, including advanced diagnostic tools, expanded screening programs, and wider therapeutic access. The development and approval of new drugs, including biologics and small molecule therapies, are expanding treatment options and meeting the needs of previously underserved patient populations. The momentum in pharmaceutical research, supported by large-scale clinical trials and public-private partnerships, is fostering rapid innovation and faster regulatory approvals. Additionally, the increasing penetration of digital health solutions and remote monitoring tools is enabling more efficient and cost-effective management of lung diseases. Health insurance coverage for advanced therapies is also improving in many countries, encouraging greater adoption and access. Heightened awareness of respiratory health following the global COVID-19 pandemic has further accelerated investments in pulmonary research and infrastructure. Moreover, the growing emphasis on personalized and precision medicine is pushing companies to develop targeted therapies that improve patient outcomes while minimizing side effects. Together, these drivers are creating a dynamic and robust environment for growth, positioning the lung disease therapeutics market as a critical pillar in global healthcare and an area of continued scientific and commercial focus.

SCOPE OF STUDY:

The report analyzes the Lung Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease (Asthma Disease, Lung Cancer Disease, Chronic Obstructive Pulmonary Disease); Drug Class (Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents, Mucolytic Drugs); Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb
• Chiesi Farmaceutici S.p.A.
• Cipla Ltd
• Gilead Sciences
• GlaxoSmithKline plc (GSK)
• Hoffmann-La Roche Ltd (Roche)
• Ionis Pharmaceuticals Inc.
• Johnson & Johnson (Janssen)
• Merck & Co. Inc.
• Mylan N.V. (part of Viatris)
• Nektar Therapeutics Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Incorporated

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Lung Disease Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Chronic Disease Burden Throws the Spotlight on Long-Term Therapeutic Management for Lung Disorders
  • Rising Air Pollution Levels Spur Demand for Preventive and Curative Pulmonary Therapies
  • Breakthrough Biologics & Targeted Therapies Expand the Addressable Market for Complex Lung Diseases
  • Aging Global Population Strengthens the Business Case for Chronic Obstructive Pulmonary Disease (COPD) Treatments
  • Digital Health Integration Accelerates Demand for Remote Monitoring and Personalized Respiratory Care Solutions
  • Surging Cases of Post-COVID Pulmonary Complications Drive Adoption of Advanced Lung Recovery Therapeutics
  • Innovations in Inhalation Drug Delivery Systems Propel Growth in Patient-Centric Treatment Models
  • Advancements in Gene & Cell Therapy Open New Frontiers in Refractory Lung Disease Management
  • Growing Emphasis on Early Diagnosis Sustains Growth Momentum for Companion Diagnostic-Linked Therapies
  • Real-World Evidence (RWE) and AI-Driven Clinical Insights Bolster Confidence in New Drug Pipelines
  • Heightened Awareness Campaigns Around Smoking Cessation Generate Demand for Preventive Therapeutic Programs
  • Shift Toward Value-Based Healthcare Models Elevates the Role of Cost-Effective, Outcome-Driven Lung Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Lung Disease Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Lung Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Lung Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Asthma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Lung Cancer Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Lung Cancer Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Lung Cancer Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Corticosteroid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Bronchodilator Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Bronchodilator Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Bronchodilator Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Antimicrobial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Antimicrobial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Antimicrobial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Mucolytic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Mucolytic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Mucolytic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• JAPAN
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• CHINA
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: China 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• EUROPE
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Lung Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Lung Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• FRANCE
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: France 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• GERMANY
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Lung Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• INDIA
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: India 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Lung Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Lung Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Lung Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Lung Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
• AFRICA
  • Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030

IV. COMPETITION